United Kingdom Daily Briefing

Financial Times reported Trump claiming the Strait of Hormuz reopening deal is 'largely negotiated' — language that immediately hit Shell (SHEL -1.40%) and the broader FTSE Energy sector (-1.27%) as markets priced the beginning of oil-price normalisation. For FTSE 100 investors, this is structurally significant: Shell and BP together represent ~12% of index weighting, meaning any sustained Brent decline mechanically drags FTSE total return even when domestic UK stocks hold. The Guardian Business injected realism: 'Even if the Iran war ended today, US fuel prices aren't likely to normalize this year' — a counter-read suggesting SHEL selling may have overshot, given US drilling expansion (FT earlier this week reported +40% output) takes time to rebuild supply.

Financial Times reported Delivery Hero is in takeover talks with Uber at a €10bn valuation, with DoorDash also circling — a deal that reshapes European food delivery and has a direct UK read-through via Just Eat's competitive position. Just Eat's FTSE 250 listing would face intensified peer consolidation pressure if Uber absorbs Delivery Hero's European assets, while Uber's UK operations would expand significantly. At €10bn enterprise value, the deal signals that tech-consumer M&A risk appetite in Europe hasn't collapsed despite macro headwinds — a selectively constructive data point for FTSE 250 domestic growth names trading at depressed multiples.

Prudential (PUK) led Friday's UK losers at -2.46%, a move that reflects its Asian EM insurance book — primarily China and South-East Asia — being repriced for sustained Iran-driven global macro uncertainty rather than any UK-specific catalyst. AstraZeneca's -1.43% adds pharma-specific selling pressure from ongoing post-Brexit UK-EU pricing renegotiations, which periodically spook institutional holders around regulatory calendar dates. Together, PUK and AZN represent an 'EM-exposed and regulatory-challenged quality names' trade unwinding at current prices — and given both remain FTSE 100 anchor stocks, a reversal on either Iran deal or Brexit pharma clarity would be FTSE supportive.